Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment ...
Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulation Scalp psoriasis affects more than 2.5 million U.S. patients Phase 2b topline data anticipated fourth quarter 2020 WESTLAKE VILLAGE, Calif., July 20, 2020 (GLOBE NEWSWIRE) …